Most Read Articles
Jairia Dela Cruz, 4 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
4 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 3 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.

Product Highlight - Dupixent

4 days ago
First and Only Biologic Therapy that specifically targets IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation (including Atopic Dermatitis and Asthma)1,2

Now locally approved for:

- Adult & adolescent (aged 12-17) patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy1
- An add-on maintenance treatment for patients (12+ years) with inadequately controlled severe asthma with type 2 inflammation1


References:
1. DUPIXENT Summary of Product Characteristics. May 2020.
2. Gandhi NA et al. Nature Rev Drug Disc 2016; 15: 35–50.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 4 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
4 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 3 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.